E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
TL;DR: Gilteritinib is a potent, second generation inhibitor of bothFLT3 and AXL, designed to address the limitations of other FLT3 inhibitors, particularly in targeting mechanisms of resistance to other drugs.
Journal ArticleDOI
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis
Naveen Pemmaraju,Bing Z. Carter,Prithviraj Bose,Nitin Jain,Tapan M. Kadia,Guillermo Garcia-Manero,Carlos E. Bueso-Ramos,Courtney D. DiNardo,Sharon D. Bledsoe,Naval Daver,Uday R. Popat,Marina Konopleva,Lingsha Zhou,Sherry Pierce,Zeev Estrov,Gautam Borthakur,Maro Ohanian,Wei Qiao,Lucia Masarova,Xuemei Wang,Po Yee Mak,Jorge E. Cortes,Elias Jabbour,Srdan Verstovsek +23 more
TL;DR: In this article, a single-center, investigator-initiated phase 2 clinical trial was conducted with a monovalent SMAC mimetic LCL161 (oral, starting dose, 1500 mg per week) in patients with intermediate to high-risk myelofibrosis.
Journal ArticleDOI
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
TL;DR: The BCR-ABL tyrosine kinase inhibitor imatinib has dramatically improved the prognosis for most patients with chronic myeloid leukemia, and it should be possible in the future to further refine treatment algorithms.
Journal ArticleDOI
Second-line Therapy and Beyond Resistance for the Treatment of Patients With Chronic Myeloid Leukemia Post Imatinib Failure
TL;DR: Successful treatment of patients with disease harboring T315I might lie in the effective combination or sequencing of these new agents with existing TKI therapies.
Journal ArticleDOI
A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.
Apostolia Maria Tsimberidou,Michael J. Keating,Elias Jabbour,Farhad Ravandi-Kashani,Susan O'Brien,Elihu H. Estey,Neby Bekele,William Plunkett,Hagop M. Kantarjian,Gautam Borthakur +9 more
TL;DR: Oxaliplatin, cytarabine, and fludarabine therapy had antileukemic activity in patients with poor-risk AML, but it was associated with toxicity.